logo

Kala Pharmaceuticals, Inc. (KALA)



Trade KALA now with
  Date
  Headline
6/20/2018 7:20:43 AM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $47 Price Target
5/15/2018 2:20:56 PM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q1 19 Estimate To -0.64 From -0.65
5/15/2018 2:20:40 PM Wedbush Is Raising Kala Pharmaceuticals, Inc. (KALA) FY18 Estimate To -2.01 From -2.10
5/15/2018 2:20:20 PM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q4 18 Estimate To -0.53 From -0.56
5/15/2018 2:20:11 PM Wedbush Is Raising Kala Pharmaceuticals, Inc. (KALA) Q3 18 Estimate To -0.51 From -0.53
5/15/2018 2:19:22 PM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q2 18 Estimate To -0.50 From -0.52
5/15/2018 2:18:59 PM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $47 Up From $46 Price Target
5/10/2018 7:10:44 AM Kala Pharma Q1 Net Loss $11.3 Mln Or $0.46/shr Vs. Net Loss $9.8 Mln Or $8.26/shr Last Year
5/9/2018 5:06:00 PM Kala Strengthens Commercial Organization In Preparation For First Product Launch
4/18/2018 8:38:28 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) 4Q18 Estimate To -0.56 From -0.61
4/18/2018 8:38:17 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) 3Q18 Estimate To -0.53 From -0.54
4/18/2018 8:37:59 AM Wedbush Is Lowering Kala Pharmaceuticals, Inc. (KALA) 2Q18 Estimate To -0.52 From -0.50
4/18/2018 8:37:49 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) 1Q18 Estimate To -0.49 From -0.45
4/9/2018 4:12:37 PM Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3/5/2018 8:05:50 AM Kala Pharmaceuticals Appoints Gregory Perry To Board
1/5/2018 7:06:01 AM Kala Reports Topline Results For Two Phase 3 Trials Of KPI-121 0.25% In Dry Eye Disease